#WeWontRest until we make treatments for rare disease less rare

Addressing the needs of patients waiting to access existing treatment and the patients living with the 95% of rare diseases where no treatments are available today means standing by the Orphan Regulation. Maintaining Europe’s world class regulatory and incentives system will continue to support further research into the next generation of treatments.